FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Today AIDS Healthcare Foundation (AHF) decried the fact that the recent campaign by Gilead Sciences Inc. to obtain approval by the U.S. Food & Drug Administration (FDA) for Truvada as PrEP (pre-exposure prophylaxis) has led to a “black market” for the drug in Florida. FDA-approval for use of Truvada—Gilead’s blockbuster HIV/AIDS treatment drug—as a possible form of HIV prevention for those NOT infected with the virus would be a first for the FDA, and a move that AHF and many other AIDS advocates believe would set a dangerous precedent.
